# Unravelling the role of the gut microbiome in antipsychotic-induced weight gain and metabolic dysfunction in humans and rodents: A systematic review

**Authors:** Maximilian Tufvesson-Alm, Louise Walsh, Sinead Pierce, Finola Keohane, Gerard Clarke, Karen O’Connor, John F. Cryan, Harriet Schellekens

PMC · DOI: 10.1080/19585969.2026.2637716 · 2026-03-10

## TL;DR

This review explores how gut microbes might contribute to weight gain and metabolic issues caused by antipsychotic drugs in humans and animals.

## Contribution

The study systematically reviews evidence linking gut microbiome changes to antipsychotic-induced weight gain and metabolic dysfunction.

## Key findings

- Antipsychotic use is associated with reduced gut microbiota diversity and altered bacterial ratios.
- Akkermansia species are consistently reduced in studies involving antipsychotic-induced weight gain.
- Probiotics and microbiota metabolites show potential in preclinical models but have limited clinical impact.

## Abstract

Second-generation antipsychotics are frequently linked to weight gain and metabolic dysfunction, yet the mechanisms driving these effects remain elusive. The gut microbiome has been proposed as a potential mediator of these adverse outcomes. This study aimed to investigate the role of the gut microbiota in antipsychotic-induced weight gain. A systematic search of PubMed and Embase was conducted. In total, 24 publications were included in this review, including clinical and preclinical observational and intervention studies. Collectively, there is strong evidence that atypical antipsychotic-induced weight gain and metabolic dysfunction is accompanied by microbiota alterations. However, there is a lack of consensus with regards to the exact mechanisms and involvement of the microbiome in antipsychotic-induced weight gain. Nevertheless, a few patterns and common observations were found across studies, such as reduced diversity, increased Firmicutes/Bacteroidetes ratio and a reduction in Akkermansia species. While microbiota-targeted interventions had generally weak effects on weight gain and metabolic dysfunction in clinical cohorts, the use of specific probiotic strains and microbiota metabolites showed promise in preclinical studies. Thus, while the relationship between antipsychotic-induced weight gain, metabolic dysfunction, and changes in the gut microbiome are evident, further research is warranted to establish definitive causal relationships and to aid in the development of precision microbiota-targeted interventions to counteract these adverse effects.

## Full-text entities

- **Genes:** APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, GHSR (growth hormone secretagogue receptor) [NCBI Gene 2693] {aka GHDP, GHS-R1a, GHSR-1a}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, HTR2C (5-hydroxytryptamine receptor 2C) [NCBI Gene 3358] {aka 5-HT1C, 5-HT2C, 5-HTR2C, 5HTR2C, HTR1C}
- **Diseases:** Weight gain (MESH:D015430), nausea (MESH:D009325), obesity (MESH:D009765), metabolic disease (MESH:D008659), inflammation (MESH:D007249), metabolic disturbances (MESH:D024821), psychiatric (MESH:D001523), diabetes (MESH:D003920), gut dysbiosis (MESH:D064806), SCZ (MESH:D012559), stomach discomfort (MESH:D013272), AAP (MESH:D009437), tardive dyskinesia (MESH:D004409), BD (MESH:D001714), excessive eating (MESH:D001068), parkinsonism (MESH:D010302), extrapyramidal symptoms (MESH:D001480), FEP (MESH:D011618), weight-loss (MESH:D015431), IRI (MESH:D007333)
- **Chemicals:** FFA (MESH:D005230), reutericyclin (MESH:C416127), inulin (MESH:D007444), cholesterol (MESH:D002784), Blood glucose (MESH:D001786), RIS (MESH:D018967), fat (MESH:D005223), clozapine (MESH:D003024), dietary fibre (MESH:D004043), TC (MESH:D013667), Triglycerides (MESH:D014280), prebiotics (MESH:D056692), dopamine (MESH:D004298), glucose (MESH:D005947), B-GOS (-), TG (MESH:D013866), OLZ (MESH:D000077152), Lurasidone (MESH:D000069056)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Mus musculus (house mouse, species) [taxon 10090], Bacillota (clostridial firmicutes, phylum) [taxon 1239], gut metagenome (species) [taxon 749906], Limosilactobacillus reuteri (species) [taxon 1598], Bacteroidia (class) [taxon 200643], Akkermansia muciniphila (species) [taxon 239935], Clostridium coccoides [taxon 1532], Rattus norvegicus (brown rat, species) [taxon 10116], Rodentia (rodent, order) [taxon 9989], Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12978182/full.md

---
Source: https://tomesphere.com/paper/PMC12978182